Autoimmune & Inflammatory Disease Novel Biologic Therapeutics Market
完整報告名稱與涵蓋範圍
Autoimmune & Inflammatory Disease Novel Biologic Therapeutics Market Size, Share & Trends Analysis Report, By Mechanism (IL-23 and IL-17 Pathway Inhibitors, TL1A, TSLP and Other Novel Cytokine Targets, B-Cell and Plasma Cell Depleting Antibodies, FcRn Inhibitors and Complement Modulators, Bispecific and Multi-Cytokine Biologics), By Indication (Inflammatory Bowel Disease, Psoriasis and Psoriatic Arthritis, Rheumatoid Arthritis and Lupus, Atopic Dermatitis and Asthma, Rare Autoimmune Diseases), By Route of Administration (Subcutaneous, Intravenous), By Distribution Channel, By Region, and Segment Forecasts, 2026-2035
報告摘要
The autoimmune and inflammatory disease novel biologic therapeutics market covers antibody and protein therapeutics with mechanisms introduced or expanded from the mid-2010s onward, including IL-23 and IL-17 pathway inhibitors, TL1A and TSLP antibodies, FcRn inhibitors, complement modulators, B-cell and plasma-cell targeted antibodies and multispecific immunology biologics, across inflammatory bowel disease, dermatology, rheumatology, respiratory and rare autoimmune indications. First-generation TNF inhibitors and their biosimilars, and small-molecule JAK inhibitors, are excluded from revenue but analysed as competitive context.
Growth is driven by the replacement of ageing TNF franchises with more selective mechanisms that deliver deeper remission, by expansion of established antibodies into new indications and by a late-stage pipeline in which TL1A inhibitors for inflammatory bowel disease, FcRn inhibitors across IgG-mediated diseases and oral or long-acting formulations feature prominently. Head-to-head trials, combination regimens and the entry of cell therapy and degraders for severe autoimmune disease are reshaping treatment algorithms, while biosimilar erosion of older biologics frees payer budgets for novel agents.
North America and Europe generate the bulk of revenue through broad reimbursement, while Japan and China are expanding access and contributing licensing partners for novel mechanisms. Competition centres on large immunology franchises complemented by specialist biotechnology companies with first-in-class assets.
The InsightAce study delivers revenue forecasts in US$ across all mechanism, indication, route of administration and distribution channel and regional segments for 2026-2035, alongside segment-level trend analysis, competitive landscape assessment and detailed company profiling.
授權報價
| Single User | $4,500 USD |
| Enterprise / Global Site Licence | $9,500 USD |
目錄 Table of Contents
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Autoimmune & Inflammatory Disease Novel Biologic Therapeutics Market Snapshot
Chapter 4. Global Autoimmune & Inflammatory Disease Novel Biologic Therapeutics Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Market Drivers
4.3. Market Challenges
4.4. Emerging Trends
4.5. Investment and Funding Analysis
4.6. Industry Analysis - Porter's Five Forces Analysis
4.7. Competitive Landscape and Market Positioning
4.8. Market Opportunity Analysis
Chapter 5. Market Segmentation 1: By Mechanism Estimates & Trend Analysis
5.1. Mechanism & Market Share, 2026 & 2035
5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analysis, 2026 to 2035, by Mechanism:
5.2.1. IL-23 and IL-17 Pathway Inhibitors
5.2.2. TL1A, TSLP and Other Novel Cytokine Targets
5.2.3. B-Cell and Plasma Cell Depleting Antibodies
5.2.4. FcRn Inhibitors and Complement Modulators
5.2.5. Bispecific and Multi-Cytokine Biologics
Chapter 6. Market Segmentation 2: By Indication Estimates & Trend Analysis
6.1. Indication & Market Share, 2026 & 2035
6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analysis, 2026 to 2035, by Indication:
6.2.1. Inflammatory Bowel Disease
6.2.2. Psoriasis and Psoriatic Arthritis
6.2.3. Rheumatoid Arthritis and Lupus
6.2.4. Atopic Dermatitis and Asthma
6.2.5. Rare Autoimmune Diseases
Chapter 7. Market Segmentation 3: By Route of Administration Estimates & Trend Analysis
7.1. Route of Administration & Market Share, 2026 & 2035
7.2. Market Size (Value US$ Mn) & Forecasts and Trend Analysis, 2026 to 2035, by Route of Administration:
7.2.1. Subcutaneous
7.2.2. Intravenous
Chapter 8. Market Segmentation 4: By Distribution Channel Estimates & Trend Analysis
8.1. Distribution Channel & Market Share, 2026 & 2035
8.2. Market Size (Value US$ Mn) & Forecasts and Trend Analysis, 2026 to 2035, by Distribution Channel:
8.2.1. Hospital Pharmacies
8.2.2. Specialty and Retail Pharmacies
Chapter 9. Autoimmune & Inflammatory Disease Novel Biologic Therapeutics Market: Regional Estimates & Trend Analysis
9.1. North America
9.1.1. United States
9.1.2. Canada
9.2. Europe
9.2.1. Germany
9.2.2. United Kingdom
9.2.3. France
9.2.4. Italy
9.2.5. Spain
9.2.6. Rest of Europe
9.3. Asia Pacific
9.3.1. China
9.3.2. Japan
9.3.3. India
9.3.4. South Korea
9.3.5. Australia
9.3.6. Southeast Asia
9.3.7. Rest of Asia Pacific
9.4. Latin America
9.4.1. Brazil
9.4.2. Mexico
9.4.3. Rest of Latin America
9.5. Middle East & Africa
9.5.1. GCC Countries
9.5.2. South Africa
9.5.3. Rest of Middle East & Africa
Chapter 10. Competitive Landscape
10.1. Company Market Positioning Analysis
10.2. Strategic Developments (Partnerships, Expansions, Product Launches, M&A)
Chapter 11. Company Profiles
11.1. AbbVie Inc.
11.2. Johnson & Johnson
11.3. Eli Lilly and Company
11.4. Sanofi
11.5. Regeneron Pharmaceuticals, Inc.
11.6. Merck & Co., Inc.
11.7. Roche Holding AG
11.8. UCB S.A.
11.9. argenx SE
11.10. Amgen Inc.
11.11. Novartis AG
11.12. AstraZeneca plc
11.13. Takeda Pharmaceutical Company Limited
11.14. Bristol Myers Squibb
11.15. Pfizer Inc.
圖表清單 List of Tables & Figures
Table 1. Global Autoimmune & Inflammatory Disease Novel Biologic Therapeutics Market Revenue Forecast by Mechanism, 2026-2035 (US$ Mn)
Figure 1. Global Autoimmune & Inflammatory Disease Novel Biologic Therapeutics Market Segmentation Overview
Table 2. Global Autoimmune & Inflammatory Disease Novel Biologic Therapeutics Market Revenue Forecast by Indication, 2026-2035 (US$ Mn)
Figure 2. Global Autoimmune & Inflammatory Disease Novel Biologic Therapeutics Market Share by Mechanism, 2026 & 2035
Table 3. Global Autoimmune & Inflammatory Disease Novel Biologic Therapeutics Market Revenue Forecast by Route of Administration, 2026-2035 (US$ Mn)
Figure 3. Novel Immunology Biologic Pipeline by Mechanism, Indication and Phase, 2026
Table 4. Global Autoimmune & Inflammatory Disease Novel Biologic Therapeutics Market Revenue Forecast by Distribution Channel, 2026-2035 (US$ Mn)
Figure 4. Global Autoimmune & Inflammatory Disease Novel Biologic Therapeutics Market Share by Indication, 2026 & 2035
Table 5. North America Autoimmune & Inflammatory Disease Novel Biologic Therapeutics Market Revenue by Country, 2026-2035 (US$ Mn)
Figure 5. Franchise Transition from TNF Inhibitors to Selective Cytokine and FcRn Mechanisms
Table 6. Europe Autoimmune & Inflammatory Disease Novel Biologic Therapeutics Market Revenue by Country, 2026-2035 (US$ Mn)
Figure 6. Asia Pacific Autoimmune & Inflammatory Disease Novel Biologic Therapeutics Growth Opportunity Analysis
Table 7. Asia Pacific Autoimmune & Inflammatory Disease Novel Biologic Therapeutics Market Revenue by Country, 2026-2035 (US$ Mn)
Figure 7. Indication Expansion Roadmap for Leading Immunology Antibodies, 2026-2035
Table 8. Latin America Autoimmune & Inflammatory Disease Novel Biologic Therapeutics Market Revenue by Country, 2026-2035 (US$ Mn)
Figure 8. Competitive Positioning of Key Autoimmune & Inflammatory Disease Novel Biologic Therapeutics Market Participants
Table 9. Middle East & Africa Autoimmune & Inflammatory Disease Novel Biologic Therapeutics Market Revenue by Country, 2026-2035 (US$ Mn)
提及公司
常見問題
這份報告可以先索取樣本嗎？
可以。建議購買前先申請樣本，提出申請後約 2 個工作天內提供，您可以先確認內容涵蓋範圍是否符合需求。
報告價格如何計算？
報告以美元標價，台幣報價依當日匯率換算並加計 5% 營業稅。不同授權版本（單人／多人／企業全站）價格不同，量子訊息會評估您的使用情境後提供最優惠報價。
下單後多久交付？如何付款？
一般 3–7 個工作天交付，實際依出版商狀況於下單前確認。收到報告確認無誤後開立台幣發票，30 天內電匯付款即可。
量子訊息有限公司為 InsightAce Analytic 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們